Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.51 |
| ▸ | ACE | P12821 | 7/20 | 0.50 |
| ▸ | MME | P08473 | 5/20 | 0.50 |
| ▸ | CPA1 | P15085 | 1/20 | 0.50 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.50 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.49 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1676845 | 1.00 | FOLH1 (0.51) | FOLH1ACEMMECPA1ACE2 | |
| SCHEMBL598433 | 0.82 | FOLH1 (0.50) | FOLH1ACEMMECPA1ACE2 | |
| SCHEMBL598434 | 0.82 | FOLH1 (0.50) | FOLH1ACEMMECPA1ACE2 | |
| SCHEMBL8393439 | 0.80 | FOLH1 (0.55) | FOLH1ACEMMECPA1ACE2 | |
| SCHEMBL547122 | 0.80 | FOLH1 (0.61) | FOLH1ACEMMECPA1ACE2 | |
| SCHEMBL1287829 | 0.80 | FOLH1 (0.61) | FOLH1ACEMMECPA1ACE2 | |
| SCHEMBL547121 | 0.80 | FOLH1 (0.61) | FOLH1ACEMMECPA1ACE2 | |
| Hydrochloric Acid SCHEMBL7310754 | 0.78 | FOLH1 (0.60) | FOLH1ACEMMECPA1ACE2 | |
| Hydrochloric Acid SCHEMBL7310747 | 0.78 | FOLH1 (0.60) | FOLH1ACEMMECPA1ACE2 | |
| Hydrochloric Acid SCHEMBL28885042 | 0.78 | FOLH1 (0.60) | FOLH1ACEMMECPA1ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098477-A1 | Method Of Producing Compound Having Anti-Hcv Activity | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2011-04-28 | — | — | US | disclosed |
| EP-1908846-A1 | METHOD OF PRODUCING COMPOUND HAVING ANTI-HCV ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098477-A1 | Method Of Producing Compound Having Anti-Hcv Activity | ERG28, HCCS, BCAT2 | FOLH1 2346/4885ACE 472/4885MME 677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.